Journal of atherosclerosis and thrombosis最新文献

筛选
英文 中文
Effect of Pemafibrate on Cerebrovascular Atherosclerosis in Patients with Stroke and Hypertriglyceridemia. 培马布特对脑卒中合并高甘油三酯血症患者脑血管粥样硬化的影响。
IF 3 2区 医学
Journal of atherosclerosis and thrombosis Pub Date : 2025-06-01 Epub Date: 2024-11-30 DOI: 10.5551/jat.65277
Takao Hoshino, Kentaro Ishizuka, Misa Seki, Megumi Hosoya, Sono Toi, Takafumi Mizuno, Satoko Arai, Sho Wako, Shuntaro Takahashi, Rie Oshima, Kazuo Kitagawa
{"title":"Effect of Pemafibrate on Cerebrovascular Atherosclerosis in Patients with Stroke and Hypertriglyceridemia.","authors":"Takao Hoshino, Kentaro Ishizuka, Misa Seki, Megumi Hosoya, Sono Toi, Takafumi Mizuno, Satoko Arai, Sho Wako, Shuntaro Takahashi, Rie Oshima, Kazuo Kitagawa","doi":"10.5551/jat.65277","DOIUrl":"10.5551/jat.65277","url":null,"abstract":"<p><strong>Aims: </strong>The Pemafibrate for Prevention of Atherosclerotic Diseases in Stroke (PPAR Stroke) study aimed to assess the effects of pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, on the progression of cerebrovascular atherosclerosis in patients with stroke and hypertriglyceridemia.</p><p><strong>Methods: </strong>Ninety-nine patients (mean age, 65.6 years; male, 74.7%) with hypertriglyceridemia and a history of stroke or transient ischemic attack of non-cardioembolic origin were included in this prospective single-arm study. Hypertriglyceridemia was defined as a fasting serum triglyceride (TG) level ≥ 150 mg/dL. All patients were treated with pemafibrate (0.2 mg or 0.1 mg/day) for 2 years. The primary outcome was change in carotid intima-media thickness (IMT) from baseline at 2 years, as assessed using carotid ultrasonography. The secondary outcomes were changes in blood biomarker levels and progression of intracranial artery stenosis on magnetic resonance angiography.</p><p><strong>Results: </strong>The mean TG level significantly decreased from 269 mg/dL at baseline to 139 mg/dL at 2 years (P<0.001) and high-density lipoprotein cholesterol level increased from 49 to 54 mg/dL (P<0.001), whereas low-density lipoprotein cholesterol level remained unchanged. Significant reductions in high-sensitivity C-reactive protein and interleukin-6 levels were also observed (P=0.003 and P=0.002, respectively). With regard to mean IMT in the internal carotid arteries, the difference was significant for the left side (1.59 mm at baseline vs. 1.52 mm at 2 years; P=0.009) and borderline significant for the right side (1.32 mm at baseline vs. 1.28 mm at 2 years; P=0.053). Among the 48 stenotic lesions in the intracranial arteries, regression and progression was observed in 9 (18.8%) and 4 (8.3%) cases, respectively.</p><p><strong>Conclusions: </strong>Pemafibrate was observed to have TG-lowering and anti-inflammatory effects and could attenuate atherosclerosis progression in the intra- and extracranial arteries of patients with stroke and hypertriglyceridemia.</p>","PeriodicalId":15128,"journal":{"name":"Journal of atherosclerosis and thrombosis","volume":" ","pages":"676-687"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12140850/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142769341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association between Genetic Risk and the Renal Function for Developing Venous Thromboembolism. 发生静脉血栓栓塞的遗传风险与肾功能之间的关系。
IF 3 2区 医学
Journal of atherosclerosis and thrombosis Pub Date : 2025-06-01 Epub Date: 2024-11-30 DOI: 10.5551/jat.65328
Zeyu Gan, Yunlong Guan, Si Li, Yifan Kong, Jun Deng, Xingjie Hao
{"title":"Association between Genetic Risk and the Renal Function for Developing Venous Thromboembolism.","authors":"Zeyu Gan, Yunlong Guan, Si Li, Yifan Kong, Jun Deng, Xingjie Hao","doi":"10.5551/jat.65328","DOIUrl":"10.5551/jat.65328","url":null,"abstract":"<p><strong>Aims: </strong>The impact of a reduced renal function on the risk of venous thromboembolism (VTE) remains controversial. The association between VTE and the renal function, as well as genetic susceptibility, requires further clarification in a large population.</p><p><strong>Methods: </strong>This study included 358,723 participants with non-renal failure from the UK Biobank. Hazard ratios (HRs) and 95% confidence intervals (CIs) for the risk of VTE incidence associated with the renal function at baseline were estimated using the Cox proportional hazards model. In addition, the relationship between the renal function and cumulative risk of VTE was visualized using Kaplan-Meier curves and restricted cubic spline (RCS). Furthermore, this study investigated the combined effects and interactions between the renal function and genetic susceptibility on the risk of VTE onset.</p><p><strong>Results: </strong>Renal function biomarkers in the highest quartile levels for urine creatinine, serum creatinine, urea, urate, cystatin C, and urine microalbumin and lowest quartile levels for the estimated glomerular filtration rate (eGFR) were associated with an elevated risk of VTE onset. For the joint analysis with genetic susceptibility, participants with both high levels of renal function biomarkers (a low eGFR) and high genetic risk had the highest risk of developing VTE, with an HR (95% CI) of 2.83 (2.46-3.26) for urine creatinine, 2.72 (2.37-3.13) for serum creatinine, 2.49 (2.18-2.84) for urea, and 2.63 (2.26-3.05) for urate, 3.52 (3.01-4.13) for cystatin C, 2.90 (2.33-3.60) for urine microalbumin, and 3.37 (2.86-3.98) for the eGFR.</p><p><strong>Conclusions: </strong>A decreased renal function increases the risk of VTE and genetic susceptibility has a positive additive effect on VTE risk. This suggests that biomarkers of the renal function may be used as predictors of VTE, especially in populations with genetic susceptibility to VTE.</p>","PeriodicalId":15128,"journal":{"name":"Journal of atherosclerosis and thrombosis","volume":" ","pages":"703-722"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12140843/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142769337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acute Pulmonary Embolism: The Clinical Value of Early Follow-Up Computed Tomography Imaging in Thrombus Regression and Rare Differential Diagnoses of Pulmonary Intimal Sarcoma. 急性肺栓塞:早期随访ct成像在肺内膜肉瘤血栓消退和罕见鉴别诊断中的临床价值。
IF 3 2区 医学
Journal of atherosclerosis and thrombosis Pub Date : 2025-06-01 Epub Date: 2025-03-11 DOI: 10.5551/jat.ED282
Norikazu Inoguchi, Akihiro Hino, Yoshihiro Fukumoto
{"title":"Acute Pulmonary Embolism: The Clinical Value of Early Follow-Up Computed Tomography Imaging in Thrombus Regression and Rare Differential Diagnoses of Pulmonary Intimal Sarcoma.","authors":"Norikazu Inoguchi, Akihiro Hino, Yoshihiro Fukumoto","doi":"10.5551/jat.ED282","DOIUrl":"10.5551/jat.ED282","url":null,"abstract":"","PeriodicalId":15128,"journal":{"name":"Journal of atherosclerosis and thrombosis","volume":" ","pages":"673-675"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12140847/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143615622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical Significance of Early Computed Tomography Scan on Thrombus Regression Rate in Acute Pulmonary Embolism: Insights from the SAKURA PE/DVT REGISTRY. 早期计算机断层扫描对急性肺栓塞血栓消退率的临床意义:来自SAKURA PE/DVT REGISTRY的见解。
IF 3 2区 医学
Journal of atherosclerosis and thrombosis Pub Date : 2025-06-01 Epub Date: 2024-12-04 DOI: 10.5551/jat.65322
Shohei Migita, Daisuke Fukamachi, Nobuhiro Murata, Yuki Saito, Kazuto Toyama, Naoya Matsumoto, Kimie Ohkubo, Eizo Tachibana, Koji Oiwa, Hironori Haruta, Kazumiki Nomoto, Ken Arima, Makoto Ichikawa, Hiroe Uchiyama, Kenichiro Tago, Masahiro Okada, Tomohiro Nakayama, Yasuo Okumura
{"title":"Clinical Significance of Early Computed Tomography Scan on Thrombus Regression Rate in Acute Pulmonary Embolism: Insights from the SAKURA PE/DVT REGISTRY.","authors":"Shohei Migita, Daisuke Fukamachi, Nobuhiro Murata, Yuki Saito, Kazuto Toyama, Naoya Matsumoto, Kimie Ohkubo, Eizo Tachibana, Koji Oiwa, Hironori Haruta, Kazumiki Nomoto, Ken Arima, Makoto Ichikawa, Hiroe Uchiyama, Kenichiro Tago, Masahiro Okada, Tomohiro Nakayama, Yasuo Okumura","doi":"10.5551/jat.65322","DOIUrl":"10.5551/jat.65322","url":null,"abstract":"<p><strong>Aims: </strong>Direct oral anticoagulants (DOACs) are used to treat venous thromboembolism (VTE). However, their impact on thrombus regression and the clinical outcomes after 2-week post-therapy computed tomography (CT) monitoring remains unexplored. This study aimed to elucidate the characteristics of patients with VTE treated with individual DOACs, assess the incidence of clinical events, and evaluate their impact on pulmonary artery thrombus regression.</p><p><strong>Methods: </strong>This prospective, multicenter study in Japan included 175 patients with VTE treated with rivaroxaban, apixaban, and edoxaban. We employed 2-week post-therapy CT monitoring to compare thrombus regression rates, patient backgrounds, and clinical outcomes.</p><p><strong>Results: </strong>Rivaroxaban users had higher body weight, hemoglobin levels, pulmonary embolism prevalence, and larger thrombus volume, but a lower prevalence of active cancer than apixaban and edoxaban users. The median thrombus regression rate after approximately 2 weeks of treatment was 89.9%, with no significant differences between the DOACs. During the 13.5-month follow-up, the recurrence or aggravation of symptomatic VTE did not differ significantly among the groups; however, the apixaban group exhibited a slightly higher major bleeding rate. Among the 95 patients receiving rivaroxaban intensive therapy, 34 (35.8%) experienced early termination due to sufficient thrombus resolution within 2 weeks compared to the standard duration group. This did not increase VTE recurrence, aggravation, or mortality.</p><p><strong>Conclusions: </strong>Substantial thrombus regression and a low incidence of VTE and bleeding support the effectiveness of DOACs. Terminating intensive therapy in one-third of the rivaroxaban group after 2-week CT monitoring did not increase the occurrence of VTE events, thereby suggesting suitability for patients at a high risk of bleeding.</p>","PeriodicalId":15128,"journal":{"name":"Journal of atherosclerosis and thrombosis","volume":" ","pages":"688-702"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12140846/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142780291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
T50 Calciprotein Crystallization and the Decreased Role of Fetuin-A in Type 2 Diabetes. T50钙蛋白结晶和胎儿素a在2型糖尿病中的作用降低。
IF 3 2区 医学
Journal of atherosclerosis and thrombosis Pub Date : 2025-06-01 Epub Date: 2024-12-25 DOI: 10.5551/jat.65351
Yu Nagakura, Tetsuo Shoji, Shinya Fukumoto, Hideki Uedono, Shinya Nakatani, Katsuhito Mori, Yuki Nagata, Yasuo Imanishi, Tomoaki Morioka, Toshio Watanabe, Masanori Emoto
{"title":"T50 Calciprotein Crystallization and the Decreased Role of Fetuin-A in Type 2 Diabetes.","authors":"Yu Nagakura, Tetsuo Shoji, Shinya Fukumoto, Hideki Uedono, Shinya Nakatani, Katsuhito Mori, Yuki Nagata, Yasuo Imanishi, Tomoaki Morioka, Toshio Watanabe, Masanori Emoto","doi":"10.5551/jat.65351","DOIUrl":"10.5551/jat.65351","url":null,"abstract":"<p><strong>Aim: </strong>Patients with type 2 diabetes mellitus (T2D) are prone to develop vascular calcification. Fetuin-A protects against vascular calcification but it increases insulin resistance. T50 calciprotein crystallization (also called serum calcification propensity) is a novel marker of calcification stress. This study examined whether T2D affects T50 and the potential role of fetuin-A in the relationship between T2D and T50.</p><p><strong>Methods: </strong>This cross-sectional study included 101 individuals with T2D and 101 individuals without diabetes (controls). T50 and fetuin-A levels were measured using the established nephelometric method and an enzyme-linked immunosorbent assay, respectively.</p><p><strong>Results: </strong>Although fetuin-A levels were higher in the T2D group, T50 was not significantly different between the T2D and control groups. In multivariable-adjusted analyses of the total population, T50 was not independently associated with the presence of T2D, fasting plasma glucose, or HbA1c, whereas T50 was significantly associated with fetuin-A, phosphate, and calcium levels. The association between T50 and fetuin-A was modified by the presence of T2D. A subgroup analysis revealed that the positive association between T50 and fetuin-A was significant but smaller in the T2D group, and that the associations of T50 with serum phosphate and calcium were more evident in the T2D group. Additional analyses showed that T50/fetuin-A ratio was lower in the T2D group and that T50/fetuin-A ratio was inversely correlated with fasting glucose and HbA1c levels.</p><p><strong>Conclusions: </strong>T2D itself was not significantly associated with T50 but T2D modified the association between T50 and fetuin-A in favor of developing vascular calcification in T2D.</p>","PeriodicalId":15128,"journal":{"name":"Journal of atherosclerosis and thrombosis","volume":" ","pages":"763-774"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12140848/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142894711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
High Plasma Levels of S-adenosylhomocysteine is Related with the Risk of All-cause and Cardiovascular Mortality in Patients with Coronary Artery Disease. 高血浆s -腺苷型同型半胱氨酸水平与冠心病患者全因死亡率和心血管死亡率相关
IF 3 2区 医学
Journal of atherosclerosis and thrombosis Pub Date : 2025-06-01 Epub Date: 2024-12-10 DOI: 10.5551/jat.65083
Si Liu, Yongyi Wang, Mengfeng Yang, Xin Dai, Ting Huang, Ruyi Liao, Hengliang Song, Peng Li, Yun Chen, Haiyan Huang, Changhua Zhang, Yunjun Xiao
{"title":"High Plasma Levels of S-adenosylhomocysteine is Related with the Risk of All-cause and Cardiovascular Mortality in Patients with Coronary Artery Disease.","authors":"Si Liu, Yongyi Wang, Mengfeng Yang, Xin Dai, Ting Huang, Ruyi Liao, Hengliang Song, Peng Li, Yun Chen, Haiyan Huang, Changhua Zhang, Yunjun Xiao","doi":"10.5551/jat.65083","DOIUrl":"10.5551/jat.65083","url":null,"abstract":"<p><strong>Aims: </strong>Plasma S-adenosylhomocysteine (SAH) level is positively associated with cardiovascular risk. However, the relationship between plasma SAH levels and the risk of all-cause and cardiovascular mortality remains unknown. This study aimed to explore the relationship between plasma SAH levels and the risk of all-cause and cardiovascular mortality in patients with coronary artery disease (CAD).</p><p><strong>Methods: </strong>Plasma SAH levels were measured in 1553 patients with CAD. The association between plasma SAH level and the risk of all-cause and cardiovascular mortality was estimated using Cox Proportional hazards regression models.</p><p><strong>Results: </strong>Relative to participants in the lowest quartile of plasma SAH levels, those in the highest quartile of plasma SAH levels had a higher risk of all-cause death (adjusted Hazard Ratio [HR], 2.15; 95% CI, 1.54-3.01; P<0.001) and cardiovascular death (adjusted HR, 2.20; 95% CI, 1.49-3.25; P=0.001) in the age- and sex-adjusted model. The results of the multivariable adjusted analysis were similar (all-cause death [adjusted HR, 1.81; 95% CI, 1.27-2.58; P=0.002] and cardiovascular death [adjusted HR, 1.84; 95% CI, 1.21-2.79; P=0.031]). The age- and sex-adjusted HRs for each 1 SD increase in plasma SAH level were 1.30 (95% CI, 1.22-1.38) for all-cause mortality, and 1.34 (95% CI, 1.25-1.43) for cardiovascular mortality, respectively. A 1 SD increase in the SAH level was associated with a 25% higher risk of total death (adjusted HR, 1.25; 95% CI, 1.17-1.34) and a 29% greater risk of cardiovascular death (adjusted HR, 1.29; 95% CI, 1.20-1.39) in multivariable adjusted analysis.</p><p><strong>Conclusions: </strong>We found that the plasma SAH level is positively correlated with the risk of all-cause and cardiovascular mortality in patients with CAD in both age- and sex-adjusted and multivariable-adjusted models.</p>","PeriodicalId":15128,"journal":{"name":"Journal of atherosclerosis and thrombosis","volume":" ","pages":"734-752"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12140845/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142813053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of Pemafibrate on Cholesterol Synthesis and Absorption: a Post-Hoc Subgroup Analysis of a Phase 2 Clinical Trial. 培马布特对胆固醇合成和吸收的影响:一项2期临床试验的事后亚组分析
IF 3 2区 医学
Journal of atherosclerosis and thrombosis Pub Date : 2025-05-29 DOI: 10.5551/jat.65707
Shizuya Yamashita, Eiichi Araki, Hidenori Arai, Koutaro Yokote, Ryohei Tanigawa, Ayumi Saito, Hideki Suganami, Sara Minamikawa, Shun Ishibashi
{"title":"Effects of Pemafibrate on Cholesterol Synthesis and Absorption: a Post-Hoc Subgroup Analysis of a Phase 2 Clinical Trial.","authors":"Shizuya Yamashita, Eiichi Araki, Hidenori Arai, Koutaro Yokote, Ryohei Tanigawa, Ayumi Saito, Hideki Suganami, Sara Minamikawa, Shun Ishibashi","doi":"10.5551/jat.65707","DOIUrl":"https://doi.org/10.5551/jat.65707","url":null,"abstract":"<p><strong>Aim: </strong>Recently, we reported that a pemafibrate extended-release (XR) formulation lowered low-density lipoprotein cholesterol (LDL-C) and cholesterol synthesis and absorption markers in a phase 2 clinical pharmacology study. Here we describe our post-hoc analysis of that study, discuss the mechanism by which pemafibrate lowers LDL-C, and suggest which patients may respond favorably to pemafibrate treatment.</p><p><strong>Methods: </strong>In the phase 2 study, patients with hypertriglyceridemia received treatment with pemafibrate immediate-release (IR) 0.2 mg/day or XR 0.4 mg/day or 0.8 mg/day. This post-hoc subgroup analysis examined the percentage change in LDL-C, apolipoprotein B (ApoB), non-HDL-C, and cholesterol synthesis and absorption markers, in subgroups by baseline LDL-C, and then determined the correlation between the percentage change in LDL-C and the percentage change in cholesterol synthesis and absorption markers.</p><p><strong>Results: </strong>Our analysis included 60 patients who received two of three formulations of the drug. A total of 78.3% (47/60) were male, 16.7% (10/60) had type 2 diabetes mellitus, and 10% (6/60) received concomitant statins. The percentage of LDL-C lowering was greater in the population with high baseline LDL-C, and similar trends were noted for the ApoB, non-HDL-C, and cholesterol synthesis and absorption markers. The percentage change in LDL-C was positively correlated with the percentage change in lathosterol, β-sitosterol, and campesterol.</p><p><strong>Conclusions: </strong>In patients with hypertriglyceridemia, results suggested that pemafibrate lowered LDL-C by inhibiting cholesterol synthesis in the liver and cholesterol absorption from the intestinal tract. This lowering effect was greater in populations with higher baseline LDL-C.</p>","PeriodicalId":15128,"journal":{"name":"Journal of atherosclerosis and thrombosis","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144173886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Serum Total Cholesterol and Fatal Subarachnoid Hemorrhage in 120,000 Japanese: A Pooled Analysis of Data from 12 Cohorts. 12万日本人血清总胆固醇与致命性蛛网膜下腔出血:来自12个队列数据的汇总分析
IF 3 2区 医学
Journal of atherosclerosis and thrombosis Pub Date : 2025-05-24 DOI: 10.5551/jat.65650
Atsushi Satoh, Hisatomi Arima, Sachiko Tanaka-Mizuno, Akira Fujiyoshi, Aya Kadota, Katsuyuki Miura, Hirotsugu Ueshima, Tomonori Okamura, Yoshitaka Murakami
{"title":"Serum Total Cholesterol and Fatal Subarachnoid Hemorrhage in 120,000 Japanese: A Pooled Analysis of Data from 12 Cohorts.","authors":"Atsushi Satoh, Hisatomi Arima, Sachiko Tanaka-Mizuno, Akira Fujiyoshi, Aya Kadota, Katsuyuki Miura, Hirotsugu Ueshima, Tomonori Okamura, Yoshitaka Murakami","doi":"10.5551/jat.65650","DOIUrl":"https://doi.org/10.5551/jat.65650","url":null,"abstract":"<p><strong>Aim: </strong>The aim of this study was to clarify the association between serum total cholesterol and fatal subarachnoid hemorrhage in Japanese men and women.</p><p><strong>Methods: </strong>The study involved a pooled analysis of individual data from 12 well-qualified cohort studies conducted in Japan. The participants were classified according to their serum total cholesterol levels: <4.14 mmol/L (<160 mg/dL), 4.14-4.64 mmol/L (160-180 mg/dL), 4.65-5.16 mmol/L (180-199 mg/dL), 5.17-5.68 mmol/L (200-219 mg/dL), 5.69-6.20 mmol/L (220-239 mg/dL), and ≥ 6.21 mmol/L (≥ 240 mg/dL). The outcome of the analysis was death from subarachnoid hemorrhage.</p><p><strong>Results: </strong>A total of 120,973 participants (70,947 women and 50,026 men) aged 18-96 years at baseline underwent follow-up for a median of 12.7 years, and 261 participants died from subarachnoid hemorrhage during this period. In women, both low (<5.69 mmol/L [<220 mg/dL]) and high (≥ 6.21 mmol/L [≥ 240 mg/dL]) serum total cholesterol levels were significantly associated with a higher risk of fatal subarachnoid hemorrhage compared with the reference group (5.69-6.20 mmol/L [220-239 mg/dL]). These associations remained significant after adjustment for confounding factors. In contrast, no associations were observed in men.</p><p><strong>Conclusion: </strong>Both low and high serum total cholesterol levels were associated with a higher risk of fatal subarachnoid hemorrhage in 70,947 female participants from 12 cohort studies throughout Japan.</p>","PeriodicalId":15128,"journal":{"name":"Journal of atherosclerosis and thrombosis","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144142609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of a Physician-led Strike Early-Strike Strong Lipid-Lowering Protocol Incorporating PCSK9 Inhibitors for Patients with Acute Myocardial Infarction. 医生主导的含PCSK9抑制剂的早期强降脂方案对急性心肌梗死患者的影响
IF 3 2区 医学
Journal of atherosclerosis and thrombosis Pub Date : 2025-05-21 DOI: 10.5551/jat.65731
Riku Arai, Yuta Hotsubo, Yuki Nakajima, Ran Sumida, Saki Mizobuchi, Shohei Migita, Yudai Tanaka, Koichiro Hori, Katsunori Fukumoto, Yasunari Ebuchi, Keisuke Kojima, Mitsumasa Sudo, Yasuo Okumura
{"title":"Impact of a Physician-led Strike Early-Strike Strong Lipid-Lowering Protocol Incorporating PCSK9 Inhibitors for Patients with Acute Myocardial Infarction.","authors":"Riku Arai, Yuta Hotsubo, Yuki Nakajima, Ran Sumida, Saki Mizobuchi, Shohei Migita, Yudai Tanaka, Koichiro Hori, Katsunori Fukumoto, Yasunari Ebuchi, Keisuke Kojima, Mitsumasa Sudo, Yasuo Okumura","doi":"10.5551/jat.65731","DOIUrl":"https://doi.org/10.5551/jat.65731","url":null,"abstract":"<p><strong>Aims: </strong>Intensive lipid-lowering therapy is recommended for secondary prevention of cardiovascular events after acute myocardial infarction (AMI). However, the prescription rate of PCSK9 inhibitors (PCSK9is) remains low among patients not achieving low-density lipoprotein (LDL) cholesterol target levels.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on 194 patients with AMI who were discharged alive and followed up as outpatients at our institution between October 2022 and October 2024. In October 2023, we implemented the Physician-led Strike Early-Strike Strong Lipid-Lowering Protocol (Physician-led Protocol) to enhance lipid management. Patients were divided into two groups: pre-protocol (October 2022-September 2023) and post-protocol (October 2023-October 2024). Patient background characteristics, lipid-lowering therapies, and LDL cholesterol levels in the chronic phase were compared between the two groups. The outcomes included post-discharge PCSK9i initiation rates and chronic-phase LDL levels.</p><p><strong>Results: </strong>While the prescription rates of strong statins and ezetimibe were similar between the groups, PCSK9i use was significantly higher in the post-protocol group than in the pre-protocol group (15.3% vs. 2.8%, p = 0.002). Furthermore, the chronic LDL levels were significantly lower in the post-protocol group than in the pre-protocol group (51.0 vs. 58.0 mg/dL, p = 0.007). Multivariate logistic regression showed that initial LDL levels and PCSK9i use were associated with achieving chronic LDL levels <55 mg/dL. Among eligible patients in the post-protocol group, 36.4% received PCSK9is.</p><p><strong>Conclusions: </strong>The physician-led protocol increased PCSK9i prescriptions, achieving a median chronic LDL level of 51 mg/dL.</p>","PeriodicalId":15128,"journal":{"name":"Journal of atherosclerosis and thrombosis","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144119733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hemostatic Activation Markers and Early Neurological Deterioration in Branch Atheromatous Disease-Related Stroke. 分支动脉粥样硬化相关中风的止血激活标志物和早期神经功能恶化。
IF 3 2区 医学
Journal of atherosclerosis and thrombosis Pub Date : 2025-05-09 DOI: 10.5551/jat.65653
Takao Hoshino, Takafumi Mizuno, Satoko Arai, Megumi Hosoya, Kentaro Ishizuka, Eiko Higuchi, Sono Toi, Kenichi Todo
{"title":"Hemostatic Activation Markers and Early Neurological Deterioration in Branch Atheromatous Disease-Related Stroke.","authors":"Takao Hoshino, Takafumi Mizuno, Satoko Arai, Megumi Hosoya, Kentaro Ishizuka, Eiko Higuchi, Sono Toi, Kenichi Todo","doi":"10.5551/jat.65653","DOIUrl":"https://doi.org/10.5551/jat.65653","url":null,"abstract":"<p><strong>Aims: </strong>Branch atheromatous disease (BAD)-related stroke, caused by atherosclerotic occlusion at the origin of a deep penetrating artery, are prone to early neurological deterioration (END). This study aimed to assess the association between hemostatic activation markers and occurrence of END in patients with BAD-related stroke.</p><p><strong>Methods: </strong>This prospective observational study included 88 patients with BAD-related stroke within 7 days of onset. On admission, plasma beta-thromboglobulin (beta-TG), platelet factor 4 (PF4), and D-dimer levels were measured. END was defined as an increase of ≥ 2 points in the total National Institutes of Health Stroke Scale (NIHSS) score or ≥ 1 point in the motor items of the NIHSS within 7 days of admission.</p><p><strong>Results: </strong>Of the 88 patients, 34 (38.6%) experienced END. Mean beta-TG (158 ng/mL vs. 102 ng/mL; P = 0.021), PF4 (61 ng/mL vs. 35 ng/mL; P = 0.024), and D-dimer (2.0 µg/mL vs. 1.2 µg/mL; P = 0.037) levels were significantly higher in patients with END than in those without END. Multivariate analysis revealed that beta-TG and PF4 levels were independently associated with the occurrence of END, with an adjusted odds ratio per 10 ng/mL increase (95% confidence interval) of 1.09 (1.01-1.20) and 1.21 (1.02-1.49), respectively. In contrast, D-dimer levels were not independent predictors. The optimal cutoff values for predicting END were 130 and 55 ng/mL for beta-TG and PF4, respectively.</p><p><strong>Conclusions: </strong>Elevated beta-TG and PF4 levels were independent predictors of END in patients with BAD-related stroke. Hence, the measurement of these platelet activation markers helps improve the risk assessment of BAD-related stroke and may provide management implications.</p>","PeriodicalId":15128,"journal":{"name":"Journal of atherosclerosis and thrombosis","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143968436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信